Accepted for/Published in: Journal of Participatory Medicine
Date Submitted: Mar 24, 2025
Open Peer Review Period: Dec 15, 2025 - Feb 15, 2026
Date Accepted: Nov 17, 2025
(closed for review but you can still tweet)
Advancing the Science of Patient Input in Drug Research and Development
ABSTRACT
Patient-centered medical product research & development (R&D) enables researchers and medical product developers to more effectively and efficiently discover and develop new therapeutic interventions that meet the needs of patients. While there is growing momentum to incorporate evidence-based patient input into decision-making processes throughout the medical product R&D life cycle, there remain a host of barriers to full implementation and integration of systematic approaches for collecting and using robust and meaningful patient input data, including lack of tools, methodologies, and parameters for soliciting and incorporating different types of patient input. This article lays out three overarching research priorities that, if effectively addressed, would help advance the science of patient input: 1) understanding the patient experience over the course of a given disease or medical condition, 2) capturing the patient perspectives and priorities on benefit-risk, and 3) incorporating patient input into clinical trial design and continuous improvement. Approaches to address each of these research priorities can better enable the incorporation of patient input throughout the medical R&D life cycle to inform decision-making on the part of researchers, medical product developers, regulators, clinicians, and patients.
Citation
Request queued. Please wait while the file is being generated. It may take some time.
Copyright
© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.